Posted: October 6, 2021 at 7 a.m. EDT|Update: 1 hour ago
TORONTO, October 6, 2021 / PRNewswire / – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic drugs to treat neurological and psychiatric disorders with unmet medical needs, today announced that Jacques Lanthier, CEO of Mindset, will attend the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
M. Lanthier will present live on Thursday October 14e To 10:00 a.m.ET. Register to attend here.
For more information about the conference or to schedule a one-to-one meeting with the Mindset leadership team, please contact KCSA Strategic Communications at [email protected]
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the premier, exclusive investor conference series that provides an interactive forum for publicly traded companies to meet and present directly with investors.
A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine cutting-edge conferencing and investor communication capabilities with a comprehensive global network of investor audiences.
Find out more about VIC and its events on www.virtualinvestorconferences.com.
About Mindset Pharma
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic drugs to treat unmet neurological and psychiatric conditions. Mindset was created to develop next-generation pharmaceutical actives that take advantage of the revolutionary therapeutic potential of psychedelic drugs. Mindset is developing several new families of new generation psychedelic compounds, as well as an innovative process for chemically synthesizing psilocybin as well as its own proprietary compounds.
For more information about Mindset, please visit our website at www.mindsetpharma.com.
This press release contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “plan”, “intend”, “believe”, “anticipate”, “estimate”, “power”, “Potential,” “” potential, “” proposed “and other similar words, or statements that certain events or conditions” may “or” will “occur. Such statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to various risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected information seeking Additional information regarding the risks and uncertainties associated with the Company’s business is contained under the heading “Risk Factors” in the Annual Information Form of the Company. e the Company for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this press release is made as of the date of this press release and the Company does not undertake to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required. by applicable law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.
View original content to download multimedia:
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.